xi's moments
Home | Companies

Berry Oncology to launch multi-cancer early detection test within the year

By Liu Zhihua | chinadaily.com.cn | Updated: 2022-05-19 12:59

Berry Oncology, a leading Chinese company in genetic testing and early screening of tumors, plans to launch an early cancer screening product within the year that is capable in detecting six prevalent tumor types in China at one time. [Photo/berryoncology.com]

Berry Oncology, a leading Chinese company in genetic testing and early screening of tumors, plans to launch an early cancer screening product within the year that is capable in detecting six prevalent tumor types in China at one time, according to a senior executive of the company on Wednesday.

Through improving screening performance and optimizing the so-called HIFI technology, its self-developed tumor testing technology, the company aims to detect more than 20 tumor types through one-time blood draw with the product in the future, Wu Jiayan, Head of Berry Oncology Institutes, told a media briefing.

Starting from the first liver cancer early screening product launched in August 2020, Berry Oncology has built early cancer screening models from multi-omics and multi-dimensional data, which lead to the emergence of the HIFI system.

It has published performance data of early screening with the HIFI system for liver cancer and multiple tumor types that include lung, gastric, colorectal, esophageal and pancreatic cancer.

Sensitivity and specificity of early screening for liver cancer reached 95.42 percent and 97.91 percent respectively, and sensitivity and specificity of early screening for multi tumor types reached 87.58 percent and 99.09 percent, respectively. The data all reached the top level within the global industry, the company said.

Zhou Jun, CEO of the company, said Berry Oncology not only focuses on the development and transformation of cutting-edge technologies, but also seeks to develop solutions with optimal balance between product cost and performance.

The company is looking forward to cooperating with all relevant stakeholders, such as insurance companies and internet healthcare platforms, to create a truly innovative and accessible ecosystem for cancer prevention, he said.

According to a report by Guosen Securities, global next-generation sequencing markets for tumors will grow at a compound annual rate of 27 percent to reach $75 billion in 2035, among which the early tumor detection market will grow at 75 percent a year on average to cover a population of 150 million.

China's early cancer screening industry is also on the fast track of development, as Chinese people are increasingly aware that early detection and intervention are crucial to increase cancer treatment efficiency and reduce mortality, and firms strive with technological innovations to meet the growing domestic market demand.

Despite all this, about 70 percent of Chinese cancer patients are already at the middle-to-late stage of the disease when they seek medical advice for the first time, according to a report by VCbeat Research that cites statistics from sources such as the International Agency for Research on Cancer. 

liuzhihua@chinadaily.com.cn

Global Edition
BACK TO THE TOP
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349